As of 15 July 2022, 401 confirmed (n=399) and probable (n=2) cases of monophasic S. Typhimurium have been identified in the EU/EEA and the United Kingdom.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.
As of 3 June 2022, 392 confirmed (n=370) and probable (n=22) cases of monophasic S. Typhimurium have been identified in the EU/EEA and the United Kingdom.
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. As of 18 May 2022, 324 cases had been reported in 12 EU/EEA countries and the UK, including two distinct strains.
On 18 May 2022, ECDC and EFSA published an update of the rapid outbreak assessment on a multi-country outbreak of monophasic Salmonella Typhimurium linked to chocolate products made at a factory in Arlon, Belgium.
As of 19 April 2022, an outbreak of 187 confirmed and probable cases of monophasic S. Typhimurium (cluster 1) has been identified in the EU/EEA and the United Kingdom.
On 12 April 2022, ECDC and EFSA published a rapid outbreak assessment on a multi-country outbreak of monophasic Salmonella Typhimurium linked to chocolate products made at a factory in Arlon, Belgium.
On 17 February 2022, the United Kingdom (UK) reported a cluster of cases with monophasic Salmonella Typhimurium sequence type 34 infection. By 8 April 2022, 150 cases had been reported in nine EU/EEA countries and the UK. Most cases are below 10 years of age and many children have been hospitalised.